Our projects
Our current program of research studies are addressing important clinical problems, including in vaccines and serious childhood infections, cystic fibrosis, hepatitis C and allergic disorders. Our research involves comparative effectiveness trials, evaluating the effectiveness of current health policy and designing Bayesian Network models to assist the development of models of care and policy. To read more about our projects, please click the boxes below.
BEAT CF
BEAT CF is an adaptive clinical trial investigating the optimal management of cystic fibrosis (CF) lung infections. The trial will aim to optimise antibiotic treatment, as well as other treatments routinely offered to patients during an exacerbation including steroid and mucolytic prescription, and chest physiotherapy.
AusVax Safety
AusVaxSafety is a national project commissioned by the Commonwealth Government to implement real time safety monitoring for routine vaccines. The project monitors the frequency of vaccine reactions reported by parents via text message.
AuTomatic
AuTOMATIC is an adaptive clinical trial to determine whether SMS reminders improve the timeliness of routine vaccination, and if so what is the optimal content and timing of such messages.
CRIPTIC
CRIPTIC aims to enhance the capacity for novel trials by building interactive patient registries (databases), a statistical and research support network, and an educational hub for adaptive trials.
FeBrile3
FeBRILe3 aims to monitor the safety of early discharge (before 48 hours) of “low-risk” infants with fever who are admitted to hospital. The safety of early discharge will be assessed by active monitoring of unplanned hospital readmission rates, other complications, and serious bacterial infections.
IMPACT CF
IMPACT CF aims to determine which health outcomes are most important to people with cystic fibrosis and their families. The project involves a series of workshops and a discrete choice experiment survey in order to prioritise and select outcomes that may be used in future clinical research.
NICE-GUT
NICE-GUT is a randomised controlled trial, which aims to assess the impact of oral nitazoxanide (an antimicrobial) on the duration of symptoms among young Aboriginal children admitted to hospital with gastroenteritis.
OPTIMUM
OPTIMUM is a randomised controlled trial that aims to assess the acceptability of reintroducing one dose of the whole cell pertussis (whooping cough) vaccine into the child immunisation schedule, and to assess whether this reduces the development of food and other allergies.
ORVAC
ORVAC is an adaptive clinical trial assessing the likely impact of an additional rotavirus vaccine dose between 6 to 12 months of age on the burden of diarrhoeal disease in remote Australian Indigenous children.
PEA
The PEA study aims to evaluate the use of a decision-making tool for supporting antibiotic selection in children with suspected urine infections. Use of the tool is expected to improve prescribing and aims to slow the emergence of antibiotic resistance.
PLATINUM C
PLATINUM C is an adaptive clinical trial which aims to help in the elimination of hepatitis C by evaluating novel ways of delivering antiviral medication and other interventions.
Adaptive Health Intelligence
We are a not-for-profit research team specialising in pragmatic and adaptive clinical trials. Our projects focus on reducing the burden of infectious diseases by improving how routinely used medications are used in clinical practice.
Contact us
We are located at:
Telethon Kids Institute
Northern Entrance, Perth Children's Hospital
15 Hospital Ave, Nedlands 6009
E: adaptivehealth@telethonkids.org.au